Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.31 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.31 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL157640 | 0.80 | SMN1; SMN2 (0.42) | MEN1NPC1RAB9AKMT2ACYP2A6 | |
| SCHEMBL15910715 | 0.77 | ALDH1A1 (0.38) | MEN1KMT2ACYP2A6CYP3A4MAPT | |
| SCHEMBL31306149 | 0.77 | CYP2A6 (0.36) | RAB9ACYP2A6MAPT | |
| SCHEMBL4070586 | 0.77 | CYP2A6 (0.36) | RAB9ACYP2A6MAPT | |
| SCHEMBL18876002 | 0.77 | HDAC3 (0.33) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL3644685 | 0.77 | ALOX15 (0.38) | MEN1NPC1GAARAB9AKMT2A | |
| SCHEMBL18875997 | 0.75 | POLB (0.39) | MEN1NPC1KMT2A | |
| SCHEMBL22504305 | 0.74 | MAPT (0.36) | CYP2A6MAPT | |
| SCHEMBL4847264 | 0.74 | CA9 (0.38) | MEN1KMT2ACYP2A6MAPT | |
| SCHEMBL6598624 | 0.74 | ALDH1A1 (0.33) | CYP2A6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3339302-A1 | PYRIDINE DERIVATIVE | Teijin Pharma Limited (JP) | 2018-06-27 | — | — | EP | claimed |
| US-20170190694-A1 | PYRIDINE DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2017-07-06 | — | — | US | claimed |
| EP-2944633-A1 | PYRIDINE DERIVATIVE | Teijin Pharma Limited (JP) | 2015-11-18 | — | — | EP | claimed |
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-15 | — | — | US | disclosed |
| EP-3339302-A1 | PYRIDINE DERIVATIVE | Teijin Pharma Limited (JP) | 2018-06-27 | — | — | EP | disclosed |
| EP-2944633-B1 | PYRIDINE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2018-01-31 | — | — | EP | disclosed |
| US-20170190694-A1 | PYRIDINE DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2017-07-06 | — | — | US | disclosed |
| US-9637469-B2 | Pyridine derivative | TEIJIN PHARMA LIMITED (JP) | 2017-05-02 | — | — | US | disclosed |
| EP-2944633-A1 | PYRIDINE DERIVATIVE | Teijin Pharma Limited (JP) | 2015-11-18 | — | — | EP | disclosed |
| EP-2616460-B1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE. | OTSUKA PHARMA CO LTD (JP) | 2015-10-28 | — | — | EP | disclosed |
| US-20150284358-A1 | PYRIDINE DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2015-10-08 | — | — | US | disclosed |
| US-9090572-B2 | Substituted quinoxalines compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-28 | — | — | US | disclosed |
| US-9090572-B2 | Substituted quinoxalines compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-28 | — | — | US | disclosed |
| US-20130261081-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 2013-10-03 | — | — | US | disclosed |
| WO-2012036253-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE. | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284358-A1 | PYRIDINE DERIVATIVE | HPRT1, XDH, NUDT1 | MEN1 1977/4885NPC1 676/4885GAA 1553/4885 |
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | CRH, MC2R, HTR3C | MEN1 672/4885NPC1 2037/4885GAA 3221/4885 |
| US-20130261081-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | MC2R, SLC6A2, CRH | MEN1 129/4885NPC1 989/4885GAA 4689/4885 |
| US-20170190694-A1 | PYRIDINE DERIVATIVE | HPRT1, XDH, NUDT1 | MEN1 1977/4885NPC1 676/4885GAA 1553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.